VT-122

Property	Information
Drug Name	VT-122 (Propranolol and Etodolac combination)
FDA Approval	No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions)
Used for	Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma
Clinical Trial Phase	Phase 2 (based on ongoing and completed trials for various cancer types)
Clinical Trial Explanation	Not specified
Common Side Effects	Higher rates of thrombocytopenia, neutropenia, and anemia were observed in some studies
OS without	In the glioblastoma study, median overall survival was 9.2 months with low-dose TMZ alone
OS with	In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122
PFS without	Not specified
PFS with	Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies
Usefulness Rating	Investigational (specific rating not provided due to limited and preliminary data)
Usefulness Explanation	Not specified
Toxicity Level	Not specified
Toxicity Explanation	Not specified

Notes: VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.

From Ben Williams Book: Not specified

Loading comments...